Antibacterials Market to 2017 - Innovative Anti-Infectives thatTarget MDR Gram-Negative Pathogens Offer SignificantRevenue...
will not significantly slow revenues in the forecast period. While the development of newantibacterials is not currently a...
3.2.2 Penicillin Antibacterials 193.2.3 Quinolone Antibacterials 203.2.4 Macrolide Antibacterials 213.3 Global Revenues fo...
5.2 Pneumonia Therapeutics Market Size 495.2.1 Total Revenue 495.2.2 Annual Cost of Treatment (ACT) 525.2.3 Treatment Usag...
7.1.1 Microbiology 767.1.2 Diagnosis 767.1.3 Treatment 767.1.4 Prevention 767.2 Atypical Bronchitis Therapeutics Market Si...
9.2.2 Annual Cost of Therapy 969.2.3 Therapeutic Patterns 979.3 Drivers and Barriers for the Sinusitis Therapeutics Market...
11.4.3 Phase II 11711.4.4 Phase I 11711.4.5 Discovery 11711.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Ass...
13.3.5 AstraZeneca Enters into Co-Development Agreement with Forest Laboratories (August 12,2009) 13413.3.6 Protea Vaccine...
14.4.3 Primary Research 14214.5 Forecasting 14314.5.1 Epidemiology-based Forecasting 14314.5.2 Expert Panels Validation 14...
Table 25: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 50Table 26: Pneumonia Therapeutics Marke...
Table 54: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 88Table 55: Sinusitis Thera...
Figure 3: Antibacterials Market, The US, Revenue Forecasts, $bn, 2002-2017 24Figure 4: Antibacterials Market, EU-5, Revenu...
Figure 31: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 87Figure 32: Tonsillitis Therapeu...
Upcoming SlideShare
Loading in...5
×

Antibacterials+Market+to+2017+-+Innovative+Anti-Infectives+that+Target+MDR+Gram-Negative+Pathogens+Offer+Significant+Revenue+Potential

183

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
183
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Antibacterials+Market+to+2017+-+Innovative+Anti-Infectives+that+Target+MDR+Gram-Negative+Pathogens+Offer+Significant+Revenue+Potential"

  1. 1. Antibacterials Market to 2017 - Innovative Anti-Infectives thatTarget MDR Gram-Negative Pathogens Offer SignificantRevenue PotentialReport Details:Published:May 2012No. of Pages: 145Price: Single User License – US$3500Corporate User License – US$10500Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-NegativePathogens Offer Significant Revenue PotentialSummaryGBI Research, the leading business intelligence provider, has released its latest report,“Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-NegativePathogens Offer Significant Revenue Potential”, which provides key data, information and analysisfor the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections,atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europeand Japan).This report offers a comprehensive insight into antibacterial market based on the seven indicationscovered. It provides a disease overview for each indication, market forecasting, drivers andbarriers, key marketed products, pipeline information and deals information for each disease in thetop seven markets, as well as profiles for the main companies operating in the market.The report is based on proprietary databases, primary and secondary research and in-houseanalysis by GBI Research’s team of industry experts to provide a comprehensive view of theantibacterials market.The market is large and established, but still seeing good growth despite this due to the increasingproblem of nosocomial infection and the increasing incidence of some bacterial diseases in thedeveloped world. Despite several patent expiries, including of Levaquin, one of the highest sellingantibacterials, growth will continue over the forecast period. Antibacterial stewardship programs forgeneral practitioners and hospitals, aimed at countering the development of resistance in bacteria,
  2. 2. will not significantly slow revenues in the forecast period. While the development of newantibacterials is not currently a hugely dynamic area, targeting multi-drug resistant TB and otherindications will require innovative solutions in the future.The antibacterials market is expected to reach $12.7 billion in 2017, growing from $11.3 billion in2010 at a CAGR of 1.7%. The market is well served currently and patent expiries are slowing theoverall growth. However, despite this saturation, hospital-acquired infections are providing animpetus to development.Scope- Overview of the global market for antibacterials.- Breakdown of the market by region.- Market analysis for each indication – including disease overviews, market forecasting, annualcost of therapy, treatment usage patterns, key marketed products and drivers and barriers.- Comprehensive pipeline analysis by indications across all phases of development.- Company profiles including SWOT analysis for major companies operating in the market.- Key deals in the antibacterials space.Reasons to buy- Make more informed business decisions from the insightful and in-depth analysis of theantibacterials market.- Identify the opportunities and challenges that exist within the antibacterials market.- Build effective strategies to launch pipeline products.- Identify the opportunities for collaboration with the participants in the antibacterials market.Get your copy of this report @http://www.reportsnreports.com/reports/144408-antibacterials-market-to-2017-innovative-anti-infectives-that-target-mdr-gram-negative-pathogens-offer-significant-revenue-potential.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 101.2 List of Figures 122 Antibacterials - Introduction 143 Antibacterials - Overview 153.1 Bacterial Classification 153.1.1 Antimicrobial Spectrum 153.1.2 Bacterial Resistance 163.2 Antibacterial Classification 163.2.1 Cephalosporin Antibacterials 16
  3. 3. 3.2.2 Penicillin Antibacterials 193.2.3 Quinolone Antibacterials 203.2.4 Macrolide Antibacterials 213.3 Global Revenues for Antibacterials 213.3.1 Global Revenue and Forecast 213.3.2 Revenue Share by Indication 233.4 The US 243.4.1 Total Revenues 243.5 Europe (The UK, France, Germany, Spain, Italy) 253.5.1 Total Revenues 253.6 Japan 273.6.1 Total Revenues 273.7 Drivers and Barriers for the Antibacterials Market 283.7.1 Drivers for the Antibacterials Market 283.7.2 Barriers for the Antibacterials Market 283.8 Opportunities 313.8.1 Alliances with Academic and Research Institutions are the Way Forward for Big Pharma 314 Tuberculosis 324.1 Overview 324.1.1 Microbiology 334.1.2 Diagnosis 334.1.3 Treatment 334.1.4 Prevention 344.2 Tuberculosis Therapeutics Market Size 354.2.1 Total Revenue 354.2.2 Average Annual Cost of Treatment (ACT) 384.2.3 Treatment Usage Patterns 394.3 Drivers and Barriers for the Tuberculosis Therapeutics Market 424.3.1 Drivers for the Tuberculosis Therapeutics Market 424.3.2 Barriers to the Tuberculosis Therapeutics Market 434.4 Product Profile of the Major Marketed Products in the Tuberculosis Market 434.4.1 Isoniazid (Isonicotinylhydrazine, INH) 434.4.2 Rifampin (RIF) 444.4.3 Pyrazinamide (PZA) 444.4.4 Ethambutol (EMB) 455 Pneumonia 465.1 Overview 465.1.1 Microbiology 465.1.2 Diagnosis 465.1.3 Treatment 475.1.4 Prevention 48
  4. 4. 5.2 Pneumonia Therapeutics Market Size 495.2.1 Total Revenue 495.2.2 Annual Cost of Treatment (ACT) 525.2.3 Treatment Usage Patterns 535.3 Drivers and Barriers to the Pneumonia Therapeutics Market 555.3.1 Drivers for the Pneumonia Therapeutics Market 555.3.2 Barriers to the Pneumonia Antibacterials Market 555.4 Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market 575.4.1 Zyvox (linezolid) 575.4.2 Zosyn (piperacillin and tazobactum) 585.4.3 Levaquin (levofloxacin) 585.4.4 Avelox (moxifloxacin) 595.4.5 Omnicef (cefnidir) 595.4.6 Tygacil (tigecycline) 605.4.7 Doribax (doripenem) 616 Urinary Tract Infections 626.1 Overview 626.1.1 Cystitis 626.1.2 Urethritis 626.1.3 Pyelonephritis 626.1.4 Microbiology 626.1.5 Diagnosis 626.1.6 Urinalysis 626.1.7 Urine Culture 626.1.8 Treatment 636.1.9 Prevention 646.2 Urinary Tract Infection Therapeutics Market Size 646.2.1 Total Revenue 646.2.2 Annual Cost of Treatment (ACT) 676.2.3 Treatment Usage Patterns 686.3 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 706.3.1 Drivers for the UTI Therapeutics Market 706.3.2 Barriers for the UTI Therapeutics Market 706.4 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market 716.4.1 Doribax (doripenem) 716.4.2 Ciprofloxacin 726.4.3 Levaquin (levafloxacin) 736.4.4 Monurol (fosfomycin tromethamine) 746.4.5 Macrobid (nitrofurantoin) 747 Atypical Bronchitis 767.1 Overview 76
  5. 5. 7.1.1 Microbiology 767.1.2 Diagnosis 767.1.3 Treatment 767.1.4 Prevention 767.2 Atypical Bronchitis Therapeutics Market Size 777.2.1 Total Revenue 777.2.2 Annual Cost of Treatment (ACT) 797.2.3 Treatment Usage Patterns 807.3 Drivers and Barriers for the Atypical Bronchitis Therapeutics Market 827.3.1 Drivers for the Atypical Bronchitis Therapeutics Market 827.3.2 Barriers for the Atypical Bronchitis Therapeutics Market 827.4 Marketed Products 838 Tonsillitis 848.1 Overview 848.1.1 Microbiology 848.1.2 Diagnosis 848.1.3 Treatment 848.1.4 Prevention 858.2 Tonsillitis Therapeutics Market Size 858.2.1 Total Revenue 858.2.2 Annual Cost of Treatment (ACT) 878.2.3 Treatment Usage Patterns 888.3 Drivers and Barriers for the Tonsillitis Therapeutics Market 908.3.1 Drivers for the Tonsillitis Therapeutics Market 908.3.2 Barriers for the Tonsillitis Therapeutics Market 908.4 Marketed Products 918.4.1 Spectracef 919 Sinusitis 929.1 Overview 929.1.1 Frontal Sinusitis (located behind the forehead) 929.1.2 Ethmoid Sinusitis (behind the bridge of the nose) 929.1.3 Sphenoid Sinusitis (behind the eyes) 929.1.4 Maxillary Sinusitis (behind the cheeks) 929.1.5 Acute Sinusitis 929.1.6 Chronic Sinusitis 929.1.7 Microbiology 939.1.8 Diagnosis 939.1.9 Treatment 939.1.10 Prevention 939.2 Sinusitis Therapeutics Market Size 949.2.1 Total Revenue 94
  6. 6. 9.2.2 Annual Cost of Therapy 969.2.3 Therapeutic Patterns 979.3 Drivers and Barriers for the Sinusitis Therapeutics Market 989.3.1 Drivers for the Sinusitis Therapeutics Market 989.3.2 Barriers for the Sinusitis Therapeutics Market 999.4 Marketed Products 999.4.1 Augmentin 999.4.2 Levaquin 1009.4.3 Doryx 10110 Otitis Media 10210.1 Overview 10210.1.1 Acute 10210.1.2 Serous 10210.1.3 Chronic Suppurative 10210.2 Otitis Media Therapeutics Market Size 10310.2.1 Total Revenue 10310.2.2 Annual Cost of Therapy 10510.2.3 Therapeutic Patterns 10610.3 Drivers and Barriers for the Otitis Media Therapeutics Market 10710.3.1 Drivers for the Otitis Media Therapeutics Market 10710.3.2 Barriers for the Otitis Media Therapeutics Market 10710.4 Marketed Products 10810.4.1 Amoxicillin 10811 Antibacterials - Pipeline Analysis 10911.1 Introduction 10911.2 Global Tuberculosis Market: Pipeline Analysis 11011.2.1 Overview 11011.2.2 Research and Development Pipeline - Phase III 11011.2.3 Research and Development Pipeline - Phase II 11111.2.4 Research and Development Pipeline - Phase I 11211.2.5 Research and Development Pipeline - Preclinical 11211.3 Global Pneumonia Therapeutics Market: Pipeline Assessment 11311.3.1 Overview 11311.3.2 NDA Filed 11311.3.3 Phase III 11311.3.4 Phase II 11411.3.5 Phase I 11511.3.6 Preclinical 11511.4 Global Urinary Tract Infection Therapeutics Market: Pipeline Assessment 11611.4.1 Overview 11611.4.2 Phase III 116
  7. 7. 11.4.3 Phase II 11711.4.4 Phase I 11711.4.5 Discovery 11711.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment 11811.5.1 Phase I 11811.6 Global Tonsillitis Therapeutics Market: Pipeline Assessment 11811.6.1 Overview 11811.7 Global Sinusitis Therapeutics Market: Pipeline Assessment 11811.7.1 Phase I 11811.8 Global Otitis Media Therapeutics Market: Pipeline Assessment 11911.8.1 Overview 11911.8.2 Phase II 11911.8.3 Preclinical 11912 Antibacterials: Competitive Landscape 12012.1 Major Players 12012.2 Major Company Profiles 12012.2.1 Pfizer 12012.2.2 Sanofi 12112.2.3 Bayer 12212.2.4 GlaxoSmithKline 12312.2.5 AstraZeneca 12412.2.6 Cubist 12512.2.7 Daiichi Sankyo 12612.2.8 Tetraphase 12712.2.9 Johnson and Johnson 12813 Antibacterials - Strategic Consolidations 12913.1 Overview - Antibacterials Market 12913.1.1 Deals by Indication 12913.1.2 Deals by Year 13013.2 Tuberculosis 13013.2.1 Mergers and Acquisitions 13013.2.2 Licensing and Co-Developments 13013.3 Pneumonia 13313.3.1 Furiex Pharmaceuticals Enters into Licensing Agreement with Janssen Pharmaceutica forJNJ-Q2 (April 19, 2011) 13313.3.2 TaiGen Biotechnology Amends its Licensing Agreement with Warner Chilcott forNemonoxacin (October 14, 2010) 13313.3.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29,2010) 13413.3.4 Paratek Pharmaceuticals Enters into Licensing Agreement with Novartis (October 8, 2009)134
  8. 8. 13.3.5 AstraZeneca Enters into Co-Development Agreement with Forest Laboratories (August 12,2009) 13413.3.6 Protea Vaccine Enters into Co-Development Agreement with GlaxoSmithKline Biologicals(June 16, 2009) 13413.3.7 Sanofi-aventis Enters into Licensing and Collaboration Agreement with Novozymes(December 22, 2008) 13513.3.8 Laboratorios Farmaceuticos ROVI Enters into Co-Development Agreement with SanofiPasteur (May 5, 2008) 13513.3.9 Aridis Pharmaceuticals Enters into Licensing Agreement with University of Iowa Research(February 19, 2008) 13513.3.10 Nektar Therapeutics Enters into Co-Development Agreement with Bayer HealthCare(August 6, 2007) 13513.3.11 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group forFACTIVE (January 4, 2007) 13613.4 UTI 13613.4.1 Teva Pharmaceutical Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey(February 21, 2008) 13613.4.2 NanoBio Enters into Licensing Agreement with University of Michigan (April 20, 2011) 13613.4.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29,2010) 13613.4.4 Depomed Amends Licensing Agreement with Madaus (April 30, 2009) 13713.5 Atypical Bronchitis 13713.5.1 Teva Pharmaceutical Industries Completes Acquisition of Ratiopharm (August 10, 2010)13713.6 Tonsillitis 13713.6.1 Meiji Seika Enters into Licensing Agreement with Cornerstone Biopharma (November 9,2006) 13713.7 Sinusitis 13813.7.1 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE(January 4, 2007) 13813.8 Otitis Media 13813.8.1 MerLion Pharmaceuticals Enters into Licensing Agreement with Alcon Pharmaceuticals forFinafloxacin (January 11, 2011) 13813.8.2 OctoPlus Enters into Licensing Agreement with Green Cross (November 22, 2006) 13814 Antibacterials - Appendix 13914.1 Market Definition 13914.2 Abbreviations 13914.3 Sources 14114.4 Research Methodology 14114.4.1 Coverage 14214.4.2 Secondary Research 142
  9. 9. 14.4.3 Primary Research 14214.5 Forecasting 14314.5.1 Epidemiology-based Forecasting 14314.5.2 Expert Panels Validation 14414.6 Geographical Landscape 14414.7 Pipeline Analysis 14414.8 Competitive Landscape 14414.9 Contact Us 14414.10 Disclaimer 1451.1 List of TablesTable 1: Antibacterials Market, Classification, Cephalosporin Antibacterials by Generations 18Table 2: Antibacterials, Classification, Penicillin Antibacterials 20Table 3: Antibacterials Market, Global, Revenue, $bn, 2002-2010 21Table 4: Antibacterials Market, Global, Revenue Forecasts, $bn, 2010-2017 22Table 5: Antibacterials Market, The US, Revenue, $bn, 2002-2010 24Table 6: Antibacterials Market, The US, Revenue Forecasts, $bn, 2010-2017 24Table 7: Antibacterials Market, EU-5, Revenue, $bn, 2002-2010 25Table 8: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2010-2017 25Table 9: Antibacterials Market, Japan, Revenue, $m, 2002-2010 27Table 10: Antibacterials Market, Japan, Revenue Forecasts, $m, 2010–2017 27Table 11: Tuberculosis Therapeutics Market, Global, Revenue, $m, 2002-2010 35Table 12: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 35Table 13: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2010 36Table 14: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 36Table 15: Tuberculosis Antibacterials Market, Global, ACT, $, 2002-2010 38Table 16: Tuberculosis Antibacterials Market, Global, ACT, $, 2010-2017 38Table 17: Tuberculosis Therapeutics Market, Global, Prevalence Population, ’000, 2002-2010 39Table 18: Tuberculosis Therapeutics Market, Global, Prevalence Population, ’000, 2010-2017 39Table 19: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-201040Table 20: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2010-201740Table 21: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, ’000,2002-2010 41Table 22: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, ’000,2010-2017 41Table 23: Pneumonia Therapeutics Market, Global, Revenue, $m, 2002-2010 49Table 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 49
  10. 10. Table 25: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 50Table 26: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 51Table 27: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 52Table 28: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 52Table 29: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-201053Table 30: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-201753Table 31: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 64Table 32: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 64Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 65Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 66Table 35: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 67Table 36: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 67Table 37: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million,2002-2010 68Table 38: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million,2010-2017 68Table 39: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 77Table 40: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 77Table 41: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 78Table 42: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 78Table 43: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-201079Table 44: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-201779Table 45: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million,2002-2010 80Table 46: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million,2010-2017 80Table 47: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 85Table 48: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 85Table 49: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 86Table 50: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 86Table 51: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 87Table 52: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 87Table 53: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 88
  11. 11. Table 54: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 88Table 55: Sinusitis Therapeutics Market, Global, Revenue, $bn, 2002-2010 94Table 56: Sinusitis Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017 94Table 57: Sinusitis Therapeutics Market, Global, Revenue by Country, $bn 2002-2010 95Table 58: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-201795Table 59: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 96Table 60: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 96Table 61: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 97Table 62: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 97Table 63: Otitis Media Therapeutics Market, Global, Revenue, $m, 2002-2010 103Table 64: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 103Table 65: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 104Table 66: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 104Table 67: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 105Table 68: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 105Table 69: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010106Table 70: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017106Table 71: Tuberculosis Therapeutics Market, Pipeline, Phase III Molecules, 2010 110Table 72: Tuberculosis Therapeutics Market, Pipeline, Phase II Molecules, 2010 111Table 73: Tuberculosis Therapeutics Market, Pipeline, Phase I Molecules, 2010 112Table 74: Tuberculosis Therapeutics Market, Pipeline, Preclinical Molecules, 2010 112Table 75: Pneumonia Therapeutics Market, Pipeline, NDA Filed Molecules, 2010 113Table 76: Pneumonia Therapeutics Market, Pipeline, Phase III Molecules, 2010 113Table 77: Pneumonia Therapeutics Market, Pipeline, Phase II Molecules, 2010 114Table 78: Pneumonia Therapeutics Market, Pipeline, Phase I Molecules, 2010 115Table 79: Pneumonia Therapeutics Market, Pipeline, Preclinical Molecules, 2010 115Table 80: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010 116Table 81: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010 117Table 82: Urinary Tract Infection Therapeutics Market, Pipeline, Phase I Molecules, 2010 117Table 83: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Molecules, 2010 117Table 84: Atypical Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118Table 85: Sinusitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118Table 86: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010 119Table 87: Otitis Media Therapeutics Market, Pipeline, Preclinical Molecules, 2010 1191.2 List of FiguresFigure 1: Antibacterials Market, Global, Revenue Forecasts, $bn, 2002-2017 21Figure 2: Antibacterials Market, Global, Revenue Share by Indication, %, 2010 23
  12. 12. Figure 3: Antibacterials Market, The US, Revenue Forecasts, $bn, 2002-2017 24Figure 4: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2002-2017 25Figure 5: Antibacterials Market, Japan, Revenue Forecasts, $m, 2002-2017 27Figure 6: Tuberculosis, Recommended Initial Therapy, 2011 33Figure 7: Tuberculosis, Treatment Flow Pattern, 2011 34Figure 8: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 35Figure 9: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 36Figure 10: Tuberculosis Therapeutics Market, Global, ACT, $, 2002-2017 38Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population, ’000, 2002-2017 39Figure 12: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2017 40Figure 13: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, ’000,2002-2017 41Figure 14: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2011 48Figure 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 49Figure 16: Pneumonia Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 50Figure 17: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 52Figure 18: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 53Figure 19: Urinary Tract Infection Therapeutics Market, Treatment of Uncomplicated UTI, 2011 63Figure 20: Urinary Tract Infection Therapeutics Market, Treatment of Complicated UTI, 2011 63Figure 21: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast, $m, 2002-201764Figure 22: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts by Country,$m, 2002-2017 65Figure 23: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 67Figure 24: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million,2002-2017 68Figure 25: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 77Figure 26: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts by Country, $m,2002-2017 78Figure 27: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-201779Figure 28: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million,2002-2017 80Figure 29: Tonsillitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 85Figure 30: Tonsillitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-201786
  13. 13. Figure 31: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 87Figure 32: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-201788Figure 33: Sinusitis Therapeutics Market, Global, Revenue Forecast, $bn, 2002-2017 94Figure 34: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-201795Figure 35: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 96Figure 36: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 97Figure 37: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 103Figure 38: Otitis Media Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 104Figure 39: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 105Figure 40: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017106Figure 41: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 110Figure 42: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 113Figure 43: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010116Figure 44: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 119Figure 45: Antibacterial Therapeutics Market, SWOT Analysis of Pfizer, 2010 120Figure 46: Antibacterial Therapeutics Market, Sanofi SWOT Profile, 2010 121Figure 47: Antibacterials Market, Bayer SWOT Profile, 2010 122Figure 48: Antibacterials Market, GSK SWOT Profile, 2010 123Figure 49: Antibacterials Market, AstraZeneca SWOT Profile, 2010 124Figure 50: Antibacterial, Cubist SWOT Profile, 2010 125Figure 51: Antibacterial, Daiichi-Sankyo SWOT Profile, 2010 126Figure 52: Antibacterial, Tetraphase SWOT Profile, 2010 127Figure 53: Antibacterial, Johnson & Johnson SWOT Profile, 2010 128Figure 54: Antibacterials Market, Global, Deals by Indication (%), 2011 129Figure 55: Antibacterials Market, Global, Deals by Year (%), 2004-2011 130Contact: sales@reportsandreports.com for more information.

×